April 2026 Research Update

This month added a clearer picture of how complement-blocking treatments are used outside of trials, and what people may experience getting to and staying on them. Across national and regional data, many people with PNH received a C5 inhibitor, but treatment could involve delays, repeated hospital visits, and long travel distances. A separate clinical dataset suggested that, over time on C5 inhibitors, some parts of the immune system move closer to typical ranges while others change little. [1] [2] [3]

In France, hospital records from 2018 to 2022 suggested that about 55.3% of identified PNH patients received a C5 inhibitor, and many people who started treatment began on eculizumab, with a substantial share later switching to ravulizumab. This helps put day-to-day treatment patterns into context, especially the idea that switching within the same drug class is common in routine care. The study focused on who received these drugs and how they were used, not on symptom outcomes. [1]

In Brazil, claims data and patient focus groups highlighted access burdens that can shape real-world treatment. The study reported an average time to starting eculizumab of 172.9 days and an average travel distance of 87.5 km for treated patients, and it also found that persistence looked very different depending on how it was measured. Focus group participants described long travel, waiting times, and limited disease awareness as issues affecting daily life and staying on treatment. [2]

In a retrospective study of 27 people with classic PNH receiving C5 inhibitors, some immune cell levels shifted toward healthier patterns over 12 to 24 months, while others stayed largely the same. CD4 and CD8 T cells gradually moved closer to typical ranges, while B cells improved only partly and remained below healthy controls. Treg cells, natural killer cells, and dendritic cells did not show clear changes, meaning immune recovery may be uneven even when complement blockade controls hemolysis. [3]

For patients and caregivers, these studies mainly add practical context rather than changing what is known about which treatments work best. The France and Brazil reports show that where someone lives and how care is organized can strongly shape how quickly treatment starts and how much travel and scheduling it may require, which can affect quality of life. The immune-cell study suggests that complement inhibitors may be linked with gradual, partial shifts in immune balance over time, but it does not prove that the drug causes these changes or that they translate into fewer infections or other day-to-day outcomes. [1] [2] [3]

This month brought two early pieces of evidence about newer PNH treatments, one looking across studies of crovalimab and one describing a single-person treatment switch. Together, they reinforce that complement-targeting therapy options are expanding, but also that safety and consistency across patients still need clearer confirmation. The strongest information here came from pooling multiple crovalimab studies, while the switching report is an early, single-patient signal. [4] [5]

A meta-analysis pooling 4 studies (275 patients) reported high rates of hemolysis control and transfusion avoidance with crovalimab (an anti-C5 antibody), alongside frequent side effects and some serious side effects. The review also reported that results varied notably across studies, which makes the exact size of benefit and the safety profile harder to pin down. Even with that uncertainty, the combined data adds to the growing evidence base for crovalimab in PNH. [4]

A single case report described a direct switch from iptacopan to pegcetacoplan without going back to a C5 inhibitor in between, and the authors reported the switch was feasible and safe for that patient. This is a narrow finding because it is one person and the report did not provide a broader comparison group. It mainly serves as a proof-of-possibility that larger studies would need to test. [5]

For patients, these studies may matter later as more data accumulates on how different complement-targeting options compare and how people transition between them. Right now, the crovalimab review supports that many patients in studies achieved control of red blood cell breakdown and avoided transfusions, while also showing that side effects were common and results differed between studies. The switching case report adds early reassurance that one specific transition was possible in one person, but it does not tell how often that approach works or who it is safest for. [4] [5]

This month strengthened the idea that PNH is closely connected to bone marrow failure, and that the size and behavior of PNH-related clones can shift over time. Studies in aplastic anemia showed that small PNH-type cell populations can appear in different settings, and that PNH clone status at diagnosis may track with different outcomes after major AA treatments. A bone marrow single-cell study also pointed toward immune pressure on normal blood-forming stem cells as a possible reason PNH clones can gain an advantage. [6] [7] [8] [9]

In a single-center study of 207 people with aplastic anemia, those who had a PNH clone at diagnosis had higher 5-year survival after immunosuppressive therapy, compared with those without a PNH clone. In the transplant group, survival looked high in both PNH-positive and PNH-negative groups, and chronic graft-versus-host disease was reported less often in the PNH-positive group. The study also reported that clone size (small vs large) did not clearly change survival or graft-versus-host disease outcomes within this dataset. [6]

Following 204 people with severe aplastic anemia treated with immunosuppression plus eltrombopag, an analysis of genetic clones described different timelines for clonal changes. It reported two patterns linked with evolution toward myeloid cancer, including early chromosome 7 abnormalities within 1 year and later genetic changes around years 4 to 5. It also reported that evolution to PNH happened in 10 of 204 patients and was tied to expansion of preexisting PIGA-mutated clones, which supports the idea that PNH can emerge from small, already-present clones. [8]

A bone marrow single-cell study compared people with larger vs smaller PNH cell fractions and found that the biggest differences were seen in the cells that looked normal, not the PNH-type stem cells. In those with large PNH fractions, normal stem and progenitor cells showed more immune-response and cell-death signals and less cell-cycling activity, while the pattern was reversed in those with smaller PNH fractions. The researchers also found multiple different PIGA mutations in each patient, consistent with strong selection for cells with the PNH phenotype. [9]

Two case reports in people taking osimertinib (a lung cancer drug) described aplastic anemia developing along with small PNH-phenotype cell populations. Both patients improved blood counts with supportive bone marrow-directed treatments, but the report stated that the link between osimertinib and aplastic anemia is not yet clear. These cases add to awareness that small PNH-like populations can be detected during bone marrow stress, without proving that they will develop into classic PNH. [7]

For patients, these studies mostly add understanding about prognosis and biology in conditions that overlap with PNH, especially aplastic anemia. The aplastic anemia outcome study suggests that having a PNH clone at diagnosis may line up with different longer-term outcomes after immunosuppression or transplant, but it does not explain why this happens or whether it applies across all centers. The clonal tracking and single-cell studies help clarify that PNH can reflect immune pressure in the bone marrow and that small PNH-related clones can expand over years, but these are research findings and do not by themselves tell what will happen for an individual person. The osimertinib cases are a reminder that small PNH-phenotype populations can show up in other medical situations, and their meaning can be uncertain. [6] [8] [9] [7]

This month included case reports showing that unusual complications and difficult treatment choices can arise in PNH, especially when resources or standard therapies differ. The cases do not establish how common these events are, but they highlight situations where careful evaluation of causes and options mattered. Taken together, they expand the list of real-world scenarios that have been reported in PNH care. [10] [11]

One case report described a woman with PNH who developed acute pancreatitis months after starting danazol and deflazacort, and she improved after both drugs were stopped along with conservative care. The authors suggested drug-induced pancreatitis as a possible explanation after other causes were excluded in their workup. The report also described a complicated illness course that included kidney injury requiring dialysis, emphasizing how multiple organs can be affected during severe hemolysis-related events. [10]

Another case report described a person with prior PNH in spontaneous remission who later developed an unprovoked blood clot, with testing showing a small PNH clone but no signs of ongoing hemolysis. The patient was treated with anticoagulation alone rather than complement inhibition, and the authors discussed uncertainty around how to approach clots when only a small clone remains. This case underlines that PNH clones can persist quietly and still raise hard questions about risk. [11]

For patients and caregivers, these reports mainly matter as awareness-building rather than as general rules. The pancreatitis case raises the possibility that some non-standard PNH medications, including danazol and corticosteroids, could be linked to rare serious side effects in some situations, but it cannot show how often this happens. The clot-in-remission case highlights that even when hemolysis is not apparent, a small PNH clone may still be found, and the best approach to clot risk in that setting is not settled. Both reports reinforce that PNH can involve complex, individualized decision-making that case reports can illustrate but not fully answer. [10] [11]